Actively Recruiting
Evaluation of Safety and Immune Response of Omicron Subvariant-Based Nuvaxovid Vaccine in Older Adults and High-Risk Individuals Previously Vaccinated Against COVID-19
Led by Sanofi · Updated on 2026-10-15
660
Participants Needed
20
Research Sites
8 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and immune response of a single dose of Sanofis Omicron subvariant-based Nuvaxovid vaccine in people aged 65 and older, as well as in individuals aged 12 to 64 who have at least one underlying health condition that increases their risk of severe COVID-19. Participants must have previously received a COVID-19 vaccine at least 90 days before getting this study vaccine. Participants will receive one intramuscular injection of the Nuvaxovid vaccine on the first day of the study. The study duration for each participant is about three months, including follow-up visits and telephone calls to monitor their health and immune response after vaccination. Throughout the study, participants will have visits on Day 1, Day 9 telephone call, Day 29, and Day 91 telephone call to assess safety and immune response. Researchers will measure antibody levels against the Omicron variant before vaccination and 28 days after. They will also monitor for any immediate or delayed side effects, including local reactions, systemic symptoms, and any serious adverse events during the three-month follow-up.
CONDITIONS
Brief Title
Study of a Recombinant Spike COVID-19 Vaccine With Matrix-M in Older Adults and People at Increased Risk of Severe COVID-19
Research Team
T
Trial Transparency email recommended (Toll free number for US & Canada)
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here